Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.

Authors: Su, Bin and Zheng, Xin and Liu, Yan and Liu, Lifeng and Xin, Ruolei and Lu, Hongyan and Huang, Chun and Bai, Lishi and Mammano, Fabrizio and Zhang, Tong and Wu, Hao and Sun, Lijun and Dai, Lili

Ultra-deep sequencing (UDS) is a powerful tool for exploring the impact on virological outcome of minority variants with low frequencies, some even <1% of the virus population. here, we compared hiv-1 minority variants at baseline, through plasma rna and pbmc dna analyses, dominant virological failure (vf) point, to evaluate impact drug-resistant (mdrvs) on outcomes.single-molecule real-time sequencing (smrts) was performed baseline dna. stanford drug resistance database used for identification evaluation resistance-associated mutations (drams).we classified 50 patients into success (vs) vf groups. found that rates reverse transcriptase inhibitor (rti) drams determined by smrts did not differ significantly within or between groups, whether based analyses. there no significant difference in level specific drugs either except dna-based analysis lamivudine, which a trend towards higher prevalence intermediate/high-level group. mdrvs corresponded mdrvs, m100i y188h. from appeared be more sensitive than detect mdrvs.detection pretreatment rti-resistant uds showed were associated with outcome. however, useful detecting patients, potentially affecting responses, suggesting potential clinical relevance ultra-deep sequencing. © author(s) 2019. published oxford university press behalf british society antimicrobial chemotherapy. all rights reserved. permissions, please email: [email protected].

Read publication